Journal: International Journal of Biological Sciences

Article Title: CCL24 recruits CCR3 + TAMs to promote immunosuppression via YAP1 activation and serves as a therapeutic target for Gracillin in colorectal cancer

doi: 10.7150/ijbs.127341

Figure Lengend Snippet: Gracillin enhances the therapeutic efficacy of anti-cancer treatments. A, Subcutaneous inoculation of MC38 cells into C57BL/6 mice, followed by treatment with 5-fluorouracil (5-FU) or Gracillin, or the combination of the two. B-C, Growth rate and weight of MC38 subcutaneous tumors. D, Tail vein inoculation of luciferase-expressing MC38 cells into C57BL/6 mice, followed by treatment with PD-1 mAb, Gracillin, or the combination of the two. E-F, Tumor cell dissemination and distribution in mice determined using the IVIS. G-H, Number of metastatic nodules formed by MC38 cells in mouse liver and lung tissues determined using HE staining. I-J, Numbers of CCR3 + Arg1 + Mrc1 + TAMs (I) or GZMB+CD8+ T cells (J) in lung and liver metastatic nodules determined using flow cytometry. Each group include 6-8 mice per group. Data are presented as bars and dots. p < 0.05 was considered statistically significant.

Article Snippet: Treatment began on day 3 post-modeling, with administration of monoclonal antibody (mAb) of PD-1 (BioXcell, BE0146, clone RMP1-14, 200 μg per mouse, i.p., every 3 days) and Gracillin (20 mg/kg) alone or in combination for 2 weeks.

Techniques: Drug discovery, Luciferase, Expressing, Staining, Flow Cytometry